Neurocrine presents data from long-term KINECT-4 study

Neurocrine (NBIX) Biosciences presented data from the long-term KINECT-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA, or valbenazine, capsules treatment. This research, “Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment”, was shared at the 2024 Psych Congress in Boston. This post hoc analysis was conducted using data from 103 participants who reached the final Week 48 visit in the open-label KINECT-4 clinical trial. Remission was defined as having a score of 1 or less in each body region on the Abnormal Involuntary Movement Scale, or AIMS. Shifts to remission were defined as a maximum item score of 2, 3 or 4 at baseline and each item score of 1 or less at Week 48. Treatment with INGREZZA resulted in tardive dyskinesia, or TD, symptom remission for the majority of patients at Week 48: 59.2% of participants had a score of 1 or less in each AIMS item; 65.0% of participants in the 40 mg dose group and 57.8% of participants in the 80 mg dose group met this remission threshold; 10% of participants had complete resolution, with a total AIMS score of 0. Of the 4 participants with a maximum item score of 2 at baseline, 50.0% reached the remission threshold. Of the 56 participants with a maximum item score of 3 at baseline, 64.3% (36/56) reached the remission threshold. Of the 43 participants with a maximum item score of 4 at baseline, 53.5% (23/43) reached the remission threshold.